

17 July 2017

Equity Research Report Update Released on Resonance Health Ltd

Resonance Health (ASX: RHT) notes the publication of an updated equity research report on the Company and the expanding future potential of its quantitative medical imaging techniques for the diagnosis and clinical management of human disease. The report highlights the potential of the recently announced advances made by the Company in the application of artificial intelligence (14 June 2017) and the launch of a bone marrow iron test (22 June 2017).

The research was published by NDF Research, an independent equity research firm who focus on life science companies publically listed on the Australian Securities Exchange (ASX). The goal of NDF Research is to introduce global investors to high-potential companies by way of sharing quality research.

The full report is available on the Resonance Health website:

www.resonancehealth.com/investors/analyst-coverage

Resonance Health develops and delivers medical imaging solutions and services to accurately and non-invasively quantify clinical parameters. This information assists clinicians in their diagnosis and management of human disease and supports pharmaceutical companies in the development of treatments. The Company's flagship product, FerriScan[®], is globally recognised as the gold standard for measurement of liver iron concentration. FerriScan is also provided as a dual service together with an assessment of cardiac iron load. The Company's more recent product, HepaFat-Scan[®], provides a measurement of volumetric liver fat fraction (VLFF) and is generating interest for improving outcomes for patients, including those with fatty liver disease.

Resonance Health is in an exciting phase of its history as it expands its portfolio of products and has developed technologies for application in additional organs including the bone marrow, pancreas, and spleen. The Company continues work on pipeline products including tools for non-invasive measurement of liver fibrosis and inflammation. The recent advancement into the era of artificial intelligence is an important milestone in the Company's strategy targeted at opening previously inaccessible markets and potential alternative distribution pathways for its expanding range of technologies.

For further information please contact:

Sander Bangma

General Manager, Resonance Health

E: SanderB@resonancehealth.com P: +61 (0)8 9286 5300